度普利尤单抗治疗大疱性类天疱疮:多中心病例系列
该多中心病例系列描述13例大疱性类天疱疮患者使用度普利尤单抗的经验,患者平均年龄76.8岁,平均病程28.8个月。92.3%(12/13)获得疾病清除或满意应答,53.8%(7/13)完全清除,未报告不良事件。结论提示度普利尤单抗可能成为BP的附加治疗。
要点
- 度普利尤单抗可使92.3%的BP患者达到疾病清除或满意应答。
- 53.8%的患者实现BP完全清除,包括既往常规治疗失败者。
- 本系列未报告不良事件,但样本小且缺乏对照和标准化评估。
核心结论
- 度普利尤单抗可能作为大疱性类天疱疮的附加治疗,使92.3%的患者获得疾病清除或满意应答,包括既往常规治疗失败者。
研究设计与样本
- 来自5个学术中心的病例系列,纳入经皮损活检(H&E染色、直接免疫荧光或BP180/BP230 ELISA之一或多项)确诊的BP患者,共13例。
主要发现
- 患者平均年龄76.8岁,度普利尤单抗启用前BP平均病程28.8个月(范围1-60个月)。
- 疾病清除或满意应答率达92.3%(12/13),其中完全清除率为53.8%(7/13)。
- 未报告不良事件。
关键数值与推荐
- 满意应答定义为临床医生记录疾病改善且患者希望继续用药,但未记录疾病完全清除。
- 疾病清除或满意应答:92.3%(12/13);完全清除:53.8%(7/13)。
临床怎么用
- 对于传统治疗失败或不耐受的BP患者,可考虑试用度普利尤单抗。
- 使用前应经皮损活检及免疫荧光或ELISA确诊BP。
局限性
- 样本量小(13例)。
- 缺乏对照组。
- 缺乏标准化评估工具。
- 缺乏标准化安全性监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bullous pemphigoid (BP) is an autoimmune blistering disorder occurring mostly in the elderly that lacks adequate treatments. OBJECTIVE: To describe our experience using dupilumab in a series of patients with BP. METHODS: This is a case series of patients from 5 academic centers receiving dupilumab for BP. Patients were eligible if they had a clinical diagnosis of BP confirmed by lesional skin biopsy evaluated by one of more of the following: hematoxylin and eosin staining, direct immunofluorescence, or enzyme-linked immunosorbent assay for BP180 or BP230, or both. RESULTS: We identified 13 patients. Patients were an average age of 76.8 years, and the average duration of BP before dupilumab initiation was 28.8 months (range, 1-60 months). Disease clearance or satisfactory response was achieved in 92.3% (12 of 13) of the patients. Satisfactory response was defined as clinician documentation of disease improvement and patient desire to stay on the medication without documentation of disease clearance. Total clearance of the BP was achieved in 53.8% (7of 13) of patients No adverse events were reported. LIMITATIONS: Include small sample size, lack of a control group, lack of a standardized assessment tool, and lack of standardized safety monitoring. CONCLUSION: Dupilumab may be an additional treatment for BP, leading to disease clearance or satisfactory response in 92.3% of patients, including in those in whom previous conventional therapy had failed.
引用
- Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series. J Am Acad Dermatol. 2020. PMID: 32179082. doi:10.1016/j.jaad.2020.01.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。